Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by snootchybootchyon May 09, 2017 4:09pm
88 Views
Post# 26222730

RE:RE:RE:RE:88 Cents tomorrow

RE:RE:RE:RE:88 Cents tomorrow
biggerr wrote: actually their guidance could be conservative because at $10/month Yosprala is just about the same price as regular aspirin but with the PPI in it to prevent aspirin from burning a hole in your stomach. They could easily get 1 million users @ $120/year 


I tihnk you read that incorrectly.  That $10/month is just the co-pay.  

Been too busy today to listen to the conference call but the financials were surprisingly good.  The cash burn has also been cut more than I thought and gives us time to develop the market for Zontivity and increase uptake of Yosprala at the new reduced prices.  Mr. Adams has alot of skin in the game so he is highly motivated to create shareholder value.  Looking forward to listening to the conference call when I get home.
<< Previous
Bullboard Posts
Next >>